24
Participants
Start Date
January 15, 2020
Primary Completion Date
December 19, 2025
Study Completion Date
March 25, 2026
Tazemetostat
"Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle.~Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity."
WITHDRAWN
Cliniques Universitaires Saint-Luc, Brussels
TERMINATED
Antwerp University Hospital, Edegem
WITHDRAWN
Hopital de la Timone, Marseille
RECRUITING
Virginia Cancer Specialists, Fairfax
COMPLETED
Florida Cancer Specialists & Research Institute, Lake Mary
TERMINATED
Institut Bergonie, Bordeaux
COMPLETED
Gabrail Cancer Center, Canton
COMPLETED
Hematology Oncology Consultants, Royal Oak
TERMINATED
Centre Oscar Lambret, Lille
COMPLETED
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
TERMINATED
MedPolonia, Poznan
COMPLETED
Mary Crowley Cancer Research, Dallas
WITHDRAWN
Oncology Consultants - Texas Medical Center, Houston
COMPLETED
Comprehensive Cancer Center of Nevada, Las Vegas
RECRUITING
Rutgers Cancer Institute, New Brunswick
TERMINATED
Institut de Cancérologie Strasbourg Europe, Strasbourg
WITHDRAWN
Biokinetica S.A Przychodnia Jozefow, Józefów
TERMINATED
Summit Clinical Research, s.r.o, Bratislava
Lead Sponsor
Sponsor GmbH
OTHER
Epizyme, Inc.
INDUSTRY